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Abstract
Purpose There is increasing pressure on mental health
providers to reduce the duration of treatments, while
retaining level of quality and effectiveness. The risk is that
the population is underserved and therefore needs new
treatment episodes. The primary aim of this study was to
investigate whether duration of treatment and return into
mental health care were related.
Methods This study examined Dutch patients with an ini-
tial treatment episode in 2009 or 2010 in specialized
mental health settings for depressive disorder
(N = 85,754). Follow-up data about treatment episodes
were available up until 2013. The data set included
demographic (age, gender), and clinical factors (comor-
bidity with other DSM-IV Axis; scores on the ‘Global
Assessment of Functioning’). Cox regression analyses were
used to assess whether duration of treatment and relapse
into mental health care were related.
Results The majority of patients did not return into mental
health care (86 %). Patients with a shorter duration of
treatment (5–250 min; 251–500 min and 751–1000 min)
were slightly more likely to return (reference group:
[1000 min) (HR 1.19 95 % CI 1.13–1.26; HR 1.11 95 %
CI 1.06–1.17; HR 1.18 95 % CI 1.11–1.25), adjusted for
demographic and clinical variables.
Conclusions The results suggest that a longer duration of
treatment may prevent return into mental health care in
some groups. However, because of the design of the study,
no causal inference can be drawn. Further research,
preferably in a RCT, is needed to determine whether the
trend towards lower intensity treatments is associated with
repeated mental health care use.
Keywords Duration of treatment  Return into treatment 
Brief therapy  Psychotherapy
Introduction
In the past decades, psychotherapy for depression shifted
from long-term psycho-analytic approaches to more brief
therapies like cognitive behavioral therapy [1]. At present
there is an increasing pressure on mental health-care pro-
viders to provide even shorter therapies, while retaining
high quality and cost-effectiveness [1]. These treatments
typically focus on increasing patients’ self-management
skills and may be offered face-to-face, by telephone or
online. There is evidence that such brief therapies are
effective [2–7]. Furthermore, many guidelines recommend
low intensity treatment as a first step in the treatment of
mild to moderate depression [8–10] and provide more
intensive treatment only to people who do not respond to
low intensity treatments [11]. Research demonstrated that
& A. M. Boerema
a.m.boerema@vu.nl
1 Department of Clinical Neuro and Developmental
Psychology, Section Clinical Psychology, Faculty of
Behavioural and Movement Sciences, Vrije Universiteit
Amsterdam, van der Boechorststraat 1, 1081 BT Amsterdam,
The Netherlands
2 EMGO? Institute for Health Care and Research, VU
University Medical Centre, van der Boechorststraat 7,
1081 BT Amsterdam, The Netherlands
3 Department of Psychiatry, VU University Medical Centre,
van der Boechorststraat 7, 1081 BT Amsterdam,
The Netherlands
4 Statistics Netherlands (CBS), Henri Faasdreef 312,
2492 JP The Hague, The Netherlands
123
Soc Psychiatry Psychiatr Epidemiol (2016) 51:1495–1507
DOI 10.1007/s00127-016-1267-7
this stepped approach is equally effective when compared
to the traditional ‘matched care’ (in which a multidisci-
plinary team matches client and therapy) [12]. A recent
meta-regression analysis demonstrated, in addition, that
duration of treatment is not associated with therapeutic
effectiveness, suggesting that brief treatments may have
equal outcomes but could be more cost effective [3]. In
contrast with this, some studies showed that a longer
duration of treatment may be more beneficial, due to the
continued improvement of patients during therapy [13].
Moreover, there is evidence that treatment duration in
mental health practice is associated with patients charac-
teristics [14]. Patients with more severe and complex
symptoms receive treatments with a longer duration [15].
On the other hand, complexity of the disorder is also
associated with a higher risk for drop out [16, 17], implying
that people with more severe symptoms possibly receive a
shorter duration of therapy even though there was no
intention to offer only brief therapy. A concern with brief
therapies is that patients might improve but perhaps not
fully recover [13]. Since residual symptoms are strongly
associated with recurrence [18, 19]; this might lead to
repeated mental health care use.
Repeated mental health care use is a relatively common
phenomenon. Findings in the Netherlands show that almost
a quarter of the people who started a treatment in 2006 for
psychological problems received treatment a second time
and 16 % entered treatment three times or more [20]. It is
also well known that depression is a condition with a high
risk of recurrence [18, 21] leading to repeated mental
health care use. Although there is considerable attention in
research on establishing treatments that reduce the risk of
recurrence in depression [22–25], there is to the best of our
knowledge no information available on the association
between the duration of the initial treatment and the risk of
return into mental health care. Gaining insight in this
association might provide better understanding of the long-
term outcomes of brief therapies. Furthermore, examining
how treatment guidelines are implemented in practice (e.g.,
how many people actually receive a brief or prolonged
therapy) could provide useful information of clinical
practice in people with depression.
The aim of this paper examines the association between
the duration of initial treatment and the risk of return into
mental health care treatment in a large naturalistic cohort
of patients treated for depression in specialized mental
health care. All patients receiving outpatient treatment in
2009 or 2010 in the Netherlands were included and follow-
up data were available for 3 years. In addition, we exam-
ined the association between duration of initial treatment
and the risk of return into mental health care for four
treatment groups as well (e.g., patients who received psy-
chotherapy only, medication only, psychotherapy and
medication, other therapy). Furthermore, we examined
which demographic (age, gender) and clinical factors
(severity of symptoms) contribute to the risk of returning
into mental health care.
Methods
Data
Data collected in routine practice were available from
mental health care providers in the Netherlands. Mental
health practitioners routinely register diagnoses and
treatments in Diagnosis Treatment Combinations (DTCs)
[26]. The DTC contains information about the type of
care (e.g., regular care or crisis), the diagnosis (DSM-IV
classification) and the received treatment (e.g., psy-
chotherapy and/or pharmacotherapy). With the DTC
system, mental health care providers are able to register
their delivered care in a systematic way. Furthermore,
the DTC information is used by health insurance com-
panies as a national and compulsory basis for reim-
bursement of the delivered treatment in mental health
care settings (e.g., a reimbursement system). Further-
more, all mental health care providers are obliged to
provide their anonymized DTC information to the DIS
system (DTC Information System) which receives,
gathers and safely stores DTC information.
The data for the present study were used in collaboration
with Statistics Netherlands (CBS). CBS has the legal right
by law to process this type of information from the DIS
system, in order to publish official national statistics about
specialized mental health care in the Netherlands. The data
included only information about the registered treatment
activities and was not traceable to individual persons. In
the present study, data were used from the period between
2009 and 2013.
Sample
Patients were included in the present study if they were
diagnosed with a depressive disorder (based on DSM-IV-
TR criteria), started a treatment in 2009 or 2010, received
outpatient treatment and were 18 years or older.
We excluded patients receiving other forms of treatment
(for example only went through diagnostic procedures, or
received inpatient treatment), patients for whom no treat-
ment duration was registered, and patients without infor-
mation on the termination of their treatment (e.g., if and
when their treatment had finished). Furthermore, we
excluded patients who were discharged from treatment, but
returned within 7 days after discharge. We hypothesize that
in those cases the treatment was probably ended for
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Duration of the treatment episode was defined as the total
time spent on face-to-face contacts in minutes. We cate-
gorized this time in: 5–250 min, 251–750 min,
751–1000 min and [1000 min. The treatment minutes
were spent on the following activities:
• Diagnostic activities (intake, psychiatric/psychological/
neurological/personality examination, intelligence test-
ing, anamnestic interview).
• Psychological therapy (including all types of psy-
chotherapy, counseling, psycho-education and other
psychological activities).
• Pharmacotherapy (time spent on consultations).
Furthermore, information was available involving the
termination of the treatment (terminated one-sided by cli-
ent or therapist; terminated in collaboration). Information
about number of sessions was not available due to
registration inconsistencies (some practitioners registered
every treatment session separately while others only reg-
ister the total treatment time as one session).
There was no specified information available on the
background and/or disciplines of the practitioners who
performed treatment. However, all practitioners are
licensed to work with patients in specialized mental health
care. They are licensed and qualified to classify diagnoses
and provide evidence-based treatments. The majority of
patients were treated in large mental health centers
(77.3 %, n = 66,293), while 22.7 % (n = 19,461) received
treatment from self-employment psychiatrists or psychol-
ogists (e.g., professionals with own practice).
Return into mental health care
Return into mental health care was defined as: a new
treatment episode within the same mental health provider
after ending the initial treatment. It was not possible to
identify patients who returned for care but switched to
another provider. Data on return was available until
December 2013, with exception of people who returned in
2013 and continued treatment in 2014. DTC data of 2014
was not yet available.
Fig. 1 Subject flow chart
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Characteristics of the sample
Demographic variables
Gender and age were the only demographic variables
available.
Clinical information
There was information available of comorbidity on all the
DSM-IV-TR Axes (I–IV) [27]. For each of the axes
comorbidity was coded as either present or absent.
Severity of complaints was assessed with the Global
Assessment of Functioning (GAF) scale [27]. The GAF
scores were registered at the start and end of the treatment.
The GAF score ranges from 1 to 100, where 100 indicates
no or few impairments in daily functioning, and 1 cate-
gorizes severe impairment in daily functioning. We cate-
gorized the GAF score into: 1–50; 51–100.
Statistical analyses
All analyses were performed using SPSS 20 and a two
sided significance level of p\ 0.05 was used in all anal-
yses. However, since multiple analyses were performed,
we used a Bonferroni correction on the results [28]. We
used the Holm–Bonferroni correction calculator (Excel)
developed by Gaetano (2013) (results available on request).
First, multiple logistic regression analysis was per-
formed to determine the association between the predictors
and longer duration of treatment ([750 min). The cut-off
point of 750 min in this specific analysis was based on the
median. We conducted a series of univariate analyses for
each predictor separately. Then, a backward multivariate
analysis was performed. The assumptions of a logistic
regression analyses were tested (linearity of the logit,
multicollinearity and residual check) and there was no
indication of any abnormality.
Second, a Cox regression model was used to test the
relation between the predictors variables and the primary
outcome, namely return into mental health care (0 = no
return; 1 = return). We conducted a series of univariate
analyses for each predictor separately. Then, a multivariate
analysis was performed to determine the effect of indi-
vidual predictors controlled for each other. Demographic
variables (gender and age), clinical variables (comorbidity
according to the DSM-IV-TR Axis, GAF score) and reason
of finishing the treatment were first entered in the Cox
regression analysis. Next, total time spent on face-to-face
contacts was entered. The hazard ratio (HR) is the increase
(or decrease) in risk of return into mental health care.
A Cox regression adjusts for the different observation
lengths of the data.
After the main analyses we examined whether the
results were influenced by the received treatment. We
divided the patients in four treatment categories: (1)
patients who received psychotherapy only (e.g., psycho-
analytic therapy, psychodynamic therapy, behavioral ther-
apy, cognitive behavioral therapy, inter personal therapy,
client focused therapy, systemic therapy, supportive ther-
apy), (2) medication only (pharmacotherapy), (3) psy-
chotherapy and medication, and (4) other therapy (e.g.,
skills training, creative therapy, psycho-education).
Results
Characteristics study sample
The study sample consisted of 64 % women (n = 54,716)
(Table 1). The mean age of the sample was 44
(SD = 13.2) years. Diagnostic activities were registered
for the majority of the sample (91 %). Supportive therapy
was the most frequently registered treatment for the
patients (44 %). At the beginning of treatment clients
scored on average 60 (SD = 9.5) on the GAF and at the
end of treatment 67 (SD = 12.3).
Return to mental health care
Of the total sample (N = 85,754), 86 % did not return into
mental health care (n = 73,677) within the observed per-
iod. The majority of patients who returned into mental
health care, did so within the first year (73 %) after ending
the initial treatment (n = 8833). More than half (56 %) of
those who returned were diagnosed with a depression again
(n = 6714), 1 % with other mood disorders (n = 142) and
7 % with an anxiety disorder (n = 897). The remaining
patients (36 %) were diagnosed with a variety of other
disorders (n = 4324). The majority of all the returning
patients (92 %) received outpatient treatment again
(n = 11,138), while 7 % returned for a crisis consult (in-
patient and outpatient) (n = 782) and 1 % for other reasons
(n = 157).
Duration of treatment and its association
with demographics and clinical variables
For duration of treatment, both univariate and multivariate
regression analyses showed significant odds ratios (OR) for
gender, age, comorbid problems on the DSM-IV Axes and
reason of termination. Patients who were female, were
younger, had comorbidity on other DSM-IV-TR axes and
patients who ended their treatment in collaboration were
more likely to receive a longer treatment ([751 min)
(Table 2).
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Table 1 Demographic and treatment characteristics of the study population and return into mental health care
Overall population
(N = 85,754) (100 %)
No return into mental health
care (n = 73,677) (85.9 %)
Return into mental health
care (n = 12,077) (14.1 %)
v2 p
N % N % N %
Demographics
Gender, women 54,716 63.8 46,999 63.8 7717 63.9 0.05 0.82
Age, mean (SD)a 44.1 (13.2) 44.2 (15.6) 43.5 (15.5)
Age 15.17 0.001*
18–45 48,288 56.3 41,291 56.0 6997 57.9
46–65 29,375 34.3 25,398 34.5 3977 32.9
[65 8091 9.4 6988 9.5 1103 9.1
Characteristics health care received
Duration in minutes 235.55 \0.001*
5–250 11,598 13.5 9633 13.1 1965 16.3
251–500 18,239 21.3 15,442 21.0 2797 23.2
501–750 13,754 16.0 11,823 16.0 1931 16.0
751–1000 11,027 12.9 9350 12.7 1677 13.9
[1000 31,136 36.3 27,429 37.2 3707 30.2
Treatment receivedb, c
Diagnostic activities 77,996 91.0 67,450 91.5 10,591 87.7 181.28 \0.001*
Psychotherapy
Psycho-analytic therapy 149 0.2 136 0.2 13 0.1 3.54 0.06
Psycho-dynamic therapy 4574 5.3 3882 5.3 692 5.7 4.37 0.04
Behavioral therapy 1589 1.9 1402 1.9 187 1.5 7.17 0.007*
Cognitive behavioral therapy 18,174 21.2 16,184 22.0 1990 16.5 187.15 \0.001*
Interpersonal therapy 1674 2.0 147 2.0 207 1.7 4.16 0.04
Client focused therapy 3754 4.4 3364 4.6 390 3.2 44.28 \0.001*
Systemic therapy 2245 2.6 1962 2.7 283 2.3 4.16 0.04
Supportive therapy, counseling 37,388 43.6 31,854 43.2 5534 45.8 28.26 \0.001*
Other therapeutic interventionsd 19,627 22.9 17,155 23.3 2472 20.5 46.61 \0.001*
Creative therapye 18,120 21.1 14,735 20.0 3385 28.0 401.37 \0.001*
Pharmacotherapy 31,886 37.2 27,269 37.0 4617 38.2 6.59 0.01
Treatment setting
Psychotherapy only 36,944 43.1 32190 43.7 4754 39.4 100.06 \0.001*
Medication only 10,789 12.6 9222 12.5 1567 13.0
Psychotherapy and medication 21,097 24.6 18,047 24.5 3050 25.3
Other therapy 16,924 19.7 14,218 19.3 2706 22.4
Severity of complaints
GAF scores, mean (SD)f
Start treatmentg 60.0 (9.4) 60.0 (9.4) 60.0 (9.7) 98.88 \0.001*
End treatmenth 67.0 (12.3) 67.0 (12.3) 66.0 (12.2) 212.44 \0.001*
As I comorbidity, yes 23,287 27.2 21,485 29.2 1802 14.9 1063.68 \0.001*
As II comorbidityi, yes 8810 10.3 8048 10.9 762 6.3 239.62 \0.001*
As III comorbidity, yes 29,234 34.1 25,500 34.6 3734 30.9 62.96 \0.001*
As IV comorbidity, yes 73,170 85.3 62,998 85.5 10172 84.2 13.57 \0.001
Reason for closing treatment 8.69 0.003*
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Since drop-out of treatment is associated with treat-
ment duration, differences between those who dropped
out and those who ended their treatment in collaboration
were collected. Those who dropped out were signifi-
cantly younger (age category 18–45: 63 %) than those
who did not (age category 18–45: 54 % p =\ 0.01). Of
the clinical variables, the patients who dropped out of
treatment had more comorbidity on Axis I (drop out:
30 %; collaboration: 26 %, p =\0.01) and lower GAF
scores at the end of treatment (drop out: 62; collabora-
tion: 69, p =\0.01).
We also repeated the regression analyses for the patients
who ended their treatment in collaboration only. The
association between treatment duration and demo-
graphic/clinical variables for this subgroup were almost
similar to those of the whole group (results available on
request).
Duration of different types of treatment and its association
with demographics and clinical variables
The univariate and multivariate regression analyses
showed similar results for gender, age, GAF score and
comorbidity with Axis I on treatment duration for the four
different treatment groups (Table 2). Furthermore, people
with comorbid axis II or axis III disorders more often
received a long treatment than patients without those
comorbid disorders, but only for those patients who
received psychotherapy or other therapy. There was no
association between comorbid axis II and III disorders and
long treatment duration for people who had received
medication or both medication and psychotherapy. Patients
with a high GAF score more often received a long
treatment than patients with a low GAF score. However,
this association was not observed for patients who received
only psychotherapy (Table 2).
Duration of treatment and its association
with return into mental health care
As shown in Table 3 both univariate and multivariate Cox
regression analyses showed significant HR for GAF score,
comorbidity with DSM-IV I, II axes and closing reason of
treatment on return into mental health care. Patients who
were younger (18–45 years), had a lower GAF score at the
beginning of treatment, without comorbidity, as well as
patients who dropped out of the treatment were more likely
to return into mental health care. Patients who received a
treatment duration between 5–250, 251–500 and
751–1000 min were more likely to return compared with
the group who received longer than 1000 min (reference
category) (HR: 1.19), 251–500 min (HR: 1.11) and
751–1000 min (HR: 1.18). There was no effect for people
who received 501–750 min of therapy.
Sensitivity analyses
To determine if the results from the Cox regression anal-
yses were moderated by severity, an interaction term (co-
morbidity As I 9 total direct time, comorbidity As
II 9 total direct time) was added to the model. The inter-
action terms were non-significant. Furthermore, additional
analyses on return into mental health care were performed
without the patients who dropped out of treatment. The
additional Cox regression analyses showed that the effect
of age was no longer significant in the multivariate
Table 1 continued
Overall population
(N = 85,754) (100 %)
No return into mental health
care (n = 73,677) (85.9 %)
Return into mental health
care (n = 12,077) (14.1 %)
v2 p
N % N % N %
Drop out client 23,055 26.9 19,675 26.7 3380 28.0
In collaboration 62,699 73.1 54,002 73.3 8697 72.0
* Significant after Bonferroni correction
a Range (18-110)
b Treatment was not restricted to one form of therapy
c For 1 % of the people (n=579) it is unknown what kind of treatment they received
d Activities cannot be categorized within forms of psychotherapy, like for example psycho-education or skills training
e Forms of therapy like drama and music therapy and other forms like psycho motoric therapy
f GAF scores range from 1-100, where 100 indicates no or few impairments in daily functioning
g n overall population = 85,233; n no return = 73,248; n return = 11,985
h n overall population = 84,547; n no return = 72,634; n return = 11,913
i Include personality disorders and other conditions that may cause problems
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Table 2 Results univariate logistic model and backward logistic regression multivariate model longer duration of treatment ([751 min)
Univariate Multivariate
OR 95 % CI p OR 95 % CI p
Determinants
Female (ref: male)
Total group 1.08 1.05–1.12 \0.001* 1.08 1.05–1.11 \0.001*
Psychotherapy only 1.13 1.08–1.18 \0.001* 1.13 1.08–1.18 \0.001*
Medication only 1.24 1.14–1.34 \0.001* 1.23 1.14–1.34 \0.001*
Psychotherapy and medication 1.11 1.05–1.18 \0.001* 1.10 1.04–1.17 0.002*
Other therapy only 1.22 1.14–1.31 \0.001* 1.21 1.12–1.30 \0.001*
Age (ref:[65)
Total group
18–45 1.46 1.39–1.53 \0.001* 1.52 1.45–1.60 \0.001*
46–65 1.36 1.29–1.42 \0.001* 1.37 1.30–1.44 \0.001*
Psychotherapy only
18–45 1.74 1.61–1.89 \0.001* 1.84 1.69–1.99 \0.001*
46–65 1.60 1.48–1.74 \0.001* 1.61 1.48–1.76 \0.001*
Medication only
18–45 1.61 1.41–1.84 \0.001* 1.47 1.28–1.69 \0.001*
46–65 1.37 1.19–1.57 \0.001* 1.30 1.13–1.49 \0.001*
Psychotherapy and medication
18–45 1.41 1.29–1.536 \0.001* 1.37 1.24–1.51 \0.001*
46–65 1.24 1.12–1.37 \0.001* 1.19 1.08–1.32 0.001*
Other therapy only
18–45 1.42 1.26–1.60 \0.001* 1.51 1.32–1.71 \0.001*
46–65 1.28 1.13–1.46 \0.001* 1.34 1.17–1.52 \0.001*
GAF score 6–10a (start) (ref: 1–5)
Total group 1.02 0.98–1.05 0.32 – – –
Psychotherapy only 1.04 0.98–1.09 0.18 – – –
Medication only 1.33 1.22–1.45 \0.001* 1.34 1.23–1.47 \0.001*
Psychotherapy and medication 1.14 1.07–1.21 \0.001* 1.14 1.07–1.22 \0.001*
Other therapy only 1.33 1.23–1.44 \0.001* 1.32 1.21–1.43 \0.001*
Comorbidity Axis I (ref: no)
Total group 1.54 1.49–1.59 \0.001* 1.59 1.54–1.64 \0.001*
Psychotherapy only 1.45 1.38–1.51 \0.001* 1.53 1.46–1.60 \0.001*
Medication only 1.95 1.79–2.13 \0.001* 1.85 1.70–2.03 \0.001*
Psychotherapy and medication 1.50 1.40–1.61 \0.001* 1.48 1.38–1.59 \0.001*
Other therapy only 1.57 1.46–1.69 \0.001* 1.64 1.51–1.79 \0.001*
Comorbidity Axis II (ref: no)
Total group 1.18 1.13–1.23 0.03 1.33 1.27–1.39 \0.001*
Psychotherapy only 1.26 1.18–1.35 \0.001* 1.43 1.33–1.53 \0.001*
Medication only 0.86 0.75–0.97 0.02 – – –
Psychotherapy and medication 0.92 0.84–1.004 0.06 – – –
Other therapy only 1.16 1.03–1.30 0.02* 1.34 1.18–1.51 \0.001*
Comorbidity Axis III (ref: no)
Total group 1.10 1.07–1.13 \0.001* 1.13 1.10–1.17 \0.001*
Psychotherapy only 1.06 1.02–1.11 0.008* 1.12 1.07–1.17 \0.001*
Medication only 1.07 0.99–1.16 0.09 – – –
Psychotherapy and medication 0.94 0.89–1.001 0.05 – – –
Other therapy only 1.08 1.001–1.16 0.05 1.14 1.06–1.24 \0.001*
Soc Psychiatry Psychiatr Epidemiol (2016) 51:1495–1507 1501
123
analyses (HR 18–45 year = 1.03; 95 % CI 0.96–1.11;
p = 0.42; HR 46–65 year = 0.94; 95 % CI 0.88–1.009;
p = 0.08; [65 ref) but the other determinants remained
almost similar (results available on request).
Duration of different treatments and its association
with return into mental health care
Univariate and multivariate regression analyses showed
similar results for gender, age, GAF score and comorbidity
with Axis I and II on the risk to return into treatment
irrespective of type of initial treatment. Furthermore, the
Cox regression analyses showed a significant HR between
return into treatment and patients who dropped out of
treatment in the group who received psychotherapy and
medication. This association was not found in the other
treatment groups. Further, comorbidity with Axes IV was
associated with a higher risk on return in the group who
received other therapy (Table 3) but not for the other
treatment groups.
The effect of duration of treatment and return into
mental health care was similar for the group who received
only psychotherapy and the group who received other
therapy (compared to the total group) (Table 3). There was
no effect of duration of treatment and return into mental
health care for the people who received medication only
and for people who received psychotherapy and medica-
tion. Sensitivity analyses were performed on all four
groups separately. The interaction terms (comorbidity Axis
I 9 total direct time, comorbidity Axis II 9 total direct
time) were not significant for all four groups.
Discussion
The aim of this study was to investigate whether duration
of treatment and return into mental health care are related.
A large dataset with naturalistic data from mental health
care providers in the Netherlands was used. The results
showed that the majority of patients (86 %) did not return
into mental health care within the observation period.
Patients who received a shorter duration of treatment were
more likely to return than patients who received a longer
duration of treatment (HR 5–205 min: 1.19; HR
251–500 min: 1.11; HR 751–1000 min: 1.18). The effect
of duration of treatment on return into mental health care
was different for patients who received medication only
and patients who received both psychotherapy and
medication.
Based on the population characteristics, the sample was
not fully comparable with other cohorts [29, 30]. The
comorbidity rates with other DSM Axis were relative low
in our study (Axis I: 27 %, Axis II: 10 %) [29, 30]. This is
most likely due to the fact that practitioners are instructed
to report comorbidity only when it influences the treatment
of the primary diagnose [26].
The most registered treatment in this sample was sup-
portive therapy (44 %). This seems striking since guideli-
nes indicate that Cognitive Behavioral Therapy (CBT),
Cognitive Therapy (CT) and Interpersonal Therapy (IPT)
are the preferred treatments in depression [2, 31]. However,
it is common in mental health practice that practitioners
work eclectically [31], possibly resulting in the use of
relevant modules of the CBT protocol or other therapies
Table 2 continued
Univariate Multivariate
OR 95 % CI p OR 95 % CI p
Comorbidity Axis IV (ref: no)
Total group 1.70 1.64–1.77 \0.001* 1.66 1.60–1.73 \0.001*
Psychotherapy only 1.53 1.44–1.62 \0.001* 1.50 1.41–1.60 \0.001*
Medication only 2.30 2.05–2.86 \0.001* 2.13 1.89–2.40 \0.001*
Psychotherapy and medication 1.91 1.76–2.07 \0.001* 1.84 1.69–1.99 \0.001*
Other therapy only 1.39 1.27–1.52 \0.001* 1.43 1.30–1.57 \0.001*
Treatment closed in collaboration (ref: drop out of treatment)
Total group 1.65 1.60–1.71 \0.001* 1.79 1.73–1.84 \0.001*
Psychotherapy only 1.86 1.77–1.95 \0.001* 1.99 1.89–2.09 \0.001*
Medication only 1.03 0.95–1.11 0.54 1.13 1.04–1.23 0.004*
Psychotherapy and medication 1.63 1.52–1.74 \0.001* 1.71 1.60–1.83 \0.001*
Other therapy only 1.58 1.47–1.770 \0.001* 1.70 1.58–1.84 \0.001*
Model psychotherapy only: v2 = 1463.41, p\ 0.0001, df = 8). Mode medication only: v2 = 509.73, p\ 0.0001, df = 7). Model psychotherapy
and medication: v2 = 631.53, p\ 0.0001, df = 7). Model other therapy: v2 = 513.404, p\ 0.0001, df = 8)
* Significant after Bonferroni correction
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Table 3 Hazard ratios of determinants of subsequent return into mental health care
Univariate Multivariate
HR 95 % CI p HR 95 % CI p HR 95 % CI p
Step 1 Step 2
Determinants
Female (ref: male)
Total group 1.005 0.97–1.04 0.81 – – – – – –
Psychotherapy only 1.04 0.98–1.11 0.16 – – – – – –
Medication only 0.96 0.87–1.06 0.41 – – – – – –
Psychotherapy and medication 0.99 0.93–1.07 0.92 – – – – – –
Other therapy only 0.99 0.92–1.08 0.82 – – – – – –
Age (ref:[65)
Total group
18–45 1.07 1.007–1.14 0.03 1.09 1.02–1.16 0.009 1.10 1.04–1.18 0.003*
46–65 1.00 0.94–1.07 0.94 1.007 0.94–1.07 0.84 1.02 0.95–1.09 0.65
Psychotherapy only
18–45 0.96 0.86–1.06 0.22 – – – – – –
46–65 0.94 0.82–1.02 0.40 – – – – – –
Medication only
18–45 1.20 1.09–1.43 0.04 1.23 1.03–1.47 0.03 1.23 1.03–1.47 0.03
46–65 1.11 0.93–1.33 0.26 1.12 0.93–1.34 0.23 1.12 0.93–1.34 0.23
Psychotherapy and medication
18–45 1.29 1.14–1.46 \0.001* 1.23 1.08–1.40 0.002 1.23 1.08–1.40 0.002*
46–65 1.12 0.98–1.28 0.10 1.08 0.95–1.25 0.25 1.08 0.95–1.247 0.25
Other therapy only
18–45 1.04 0.91–1.18 0.58 – – – – – –
46–65 0.99 0.86–1.13 0.83 – – – – – –
GAF score 6–10a (start) (ref: 1–5)
Total group 0.81 0.78–0.84 \0.001* 0.80 0.76–0.82 0.000 0.78 0.75–0.82 \0.001*
Psychotherapy only 0.82 0.77–0.88 \0.001* 0.78 0.73–0.84 0.000 0.78 0.73–0.84 \0.001*
Medication only 0.87 0.79–0.98 0.02 0.86 0.77–0.95 0.005 0.86 0.77–0.95 0.005*
Psychotherapy and medication 0.85 0.79–0.91 \0.001* 0.86 0.80–0.92 \0.001 0.86 0.80–0.92 \0.001*
Other therapy only 0.76 0.70–0.82 \0.001* 0.71 0.65–0.78 \0.001 0.73 0.67–0.80 \0.001*
Comorbidity Axis I (ref: no)
Total group 0.45 0.43–0.47 \0.001* 0.41 0.39–0.43 \0.001 0.42 0.40–0.44 \0.001*
Psychotherapy only 0.46 0.42–0.50 \0.001* 0.42 0.39–0.45 \0.001 0.43 0.39–0.46 \0.001*
Medication only 0.46 0.40–0.53 \0.001* 0.43 0.37–0.50 \0.001 0.43 0.37–0.50 \0.001*
Psychotherapy and medication 0.52 0.47–0.57 \0.001* 0.46 0.42–0.50 \0.001 0.46 0.42–0.50 \0.001*
Other therapy only 0.36 0.32–0.41 \0.001* 0.35 0.31–0.39 \0.001 0.36 0.32–0.41 \0.001*
Comorbidity Axis II (ref: no)
Total group 0.58 0.54–0.62 \0.001* 0.47 0.44–0.51 \0.001 0.47 0.44–0.51 \0.001*
Psychotherapy only 0.57 0.50–0.64 \0.001* 0.46 0.41–0.52 \0.001 0.46 0.41–0.52 \0.001*
Medication only 0.62 0.51–0.76 \0.001* 0.52 0.42–0.63 \0.001 0.52 0.42–0.63 \0.001*
Psychotherapy and medication 0.54 0.47–0.62 \0.001* 0.44 0.39–0.51 \0.001 0.44 0.39–0.51 \0.001*
Other therapy only 0.63 0.53–0.74 \0.001* 0.51 0.43–0.61 \0.001 0.52 0.44–0.61 \0.001*
Comorbidity Axis III (ref: no)
Total group 0.86 0.83–0.97 0.001* 0.89 0.85–0.92 \0.001 0.89 0.86–0.93 0.02
Psychotherapy only 0.91 0.86–0.97 0.005* 0.91 0.86–0.97 0.005 0.92 0.86–0.98 0.007*
Medication only 0.81 0.73–0.90 \0.001* 0.86 0.77–0.95 \0.001 0.86 0.77–0.95 \0.001*
Psychotherapy and medication 0.78 0.73–0.85 0.001* 0.83 0.77–0.90 \0.001 0.83 0.77–0.90 \0.001*
Other therapy only 0.88 0.81–0.96 0.002* 0.0.91 0.83–0.99 \0.001 0.0.91 0.83–0.98 \0.001*




HR 95 % CI p HR 95 % CI p HR 95 % CI p
Step 1 Step 2
Comorbidity Axis IV (ref: no)
Total group 0.92 0.88–1.06 0.37 – – – – – –
Psychotherapy only 0.99 0.92–1.09 0.99 – – – – – –
Medication only 0.86 0.75–0.98 0.02 – – – – – –
Psychotherapy and medication 1.06 0.96–1.18 0.27 1.13 1.02–1.26 0.02 1.13 1.02–1.26 0.02
Other therapy only 0.79 0.72–0.86 \0.001* 0.85 0.77–0.93 0.02 0.87 0.79–0.95 0.003*
Treatment closed in collaboration (ref: drop out of treatment)
Total group 0.94 0.91–0.98 0.004* 0.93 0.89–0.96 \0.001 0.94 0.90–0.98 \0.001*
Psychotherapy only 0.96 0.90–1.03 0.22 – – – – – –
Medication only 1.05 0.94–1.16 0.40 – . – – – –
Psychotherapy and medication 0.83 0.77–0.90 \0.001* 0.83 0.77–0.90 \0.001 0.83 0.77–0.90 \0.001*
Other therapy only 1.04 0.96–0.1.13 0.35 – – – – – –
Duration treatment (ref:[1000 min)
Total group
5–250 min 1.34 1.27–1.41 \0.001* 1.19 1.13–1.26 \0.001*
251–500 min 1.21 1.16–1.28 \0.001* 1.11 1.06–1.17 \0.001*
501–750 min 1.11 1.05–1.18 \0.001* 1.04 0.99–1.10 0.14
751–1000 min 1.24 1.17–1.31 \0.001* 1.18 1.11–1.25 \0.001*
Psychotherapy only
5–250 min 1.43 1.30–1.57 \0.001* 1.26 1.15–1.39 \0.001*
251–500 min 1.25 1.15–1.35 \0.001* 1.14 1.05–1.24 0.001
501–750 min 1.09 1.09–1.19 0.05 1.006 0.92–1.10 0.89
751–1000 min 1.33 1.33–1.45 \0.001* 1.24 1.14–1.36 \0.001*
Medication only
5–250 min 1.14 0.99–1.31 0.08 1.02 0.88–1.18 0.75
251–500 min 1.13 0.98–1.30 0.10 1.00 0.87–1.15 0.99
501–750 min 1.30 1.11–1.51 0.001* 1.21 1.04–1.41 0.02
751–1000 min 1.16 0.98–1.38 0.09 1.12 0.94–1.33 0.20
Psychotherapy and medication
5–250 min 0.87 0.73–1.04 0.12 0.81 0.68–0.96 0.02
251–500 min 1.11 0.99–1.23 0.07 1.04 0.93–1.16 0.47
501–750 min 1.06 0.95–1.18 0.31 1.004 0.90–1.12 0.95
751–1000 min 1.32 1.19–1.45 \0.001* 1.26 1.13–1.39 \0.001*
Other therapy only
5–250 min 1.90 1.68–2.16 \0.001* 1.67 1.47–1.89 \0.001*
251–500 min 1.66 1.47–1.88 \0.001* 1.53 1.34–1.73 \0.001*
501–750 min 1.50 1.30–1.72 \0.001* 1.43 1.24–1.64 \0.001*
751–1000 min 1.27 1.07–1.50 0.006* 1.26 1.06–1.49 0.008*
HR hazard ration, CI confidence interval
* Significant after Bonferroni correction
a GAF scores range from 1 to 100, where 100 indicates no or few impairments in daily functioning
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and therefore register the treatment as supportive therapy.
In addition, some psychiatrists report their consultations
concerning medication follow-ups as supportive therapy;
this may also explain the high percentage.
The data on return into mental health care showed that the
majority of patients did not return (86 %). This percentage
seems rather high, especially because several studies show
that relapse rates for depression are high [18, 32], leading to
frequent mental health care use. A positive explanation is
that the treatments were effective for a majority of patients.
Other explanations are that patients returned after our
observation period, that they switched provider, or sought
help in primary care or other settings. All this might have led
to an underestimation of return into mental health care.
Unfortunately, there was no possibility to examine under-
estimations of return in the present data sample. However,
comparable data from other registries showed that about a
quarter (26 %) of patients with a depression diagnosis switch
provider when they return for depression to mental health
providers (data not presented).
There is an increasing pressure on mental health-care
systems to decrease the length of treatment, while retaining
effectiveness [1]. While there is evidence that low intensity
and brief treatments are effective [2–11], there is a lack of
knowledge on the long-term outcome. The data in our study
showed that patients who received a treatment duration of
shorter than 500 min and 751–1000 min, were more likely to
return compared with patients who received more than
1000 min, even when controlled for severity of symptoms.
However, there is no clear line in the results, meaning that the
effect of 5–250 min is similar to the effect of 751–1000 min.
In addition there is no effect for the group who received
501–750 min. For patients who received other therapy (e.g.,
creative therapy, psycho-education), there was an association
between all the different durations of treatment (5–250 min,
251–500 min, 501–750 min and 751–1000 min) and return
into mental health care. However, similar to the results in
patients who received psychotherapy, there is no clear line in
the results, meaning that the effects of 5–250, 251–500,
501–750 and 751–1000 min are similar. In patients who
received medication, no association between duration of
treatment and return in mental health care was found.
A possible explanation for the differences between the
groups is the purpose of the treatment. For example, mul-
tidisciplinary guidelines recommend that people who use
pharmacotherapy return to their practitioner once in a while
to examine the effect and/or stabilization of the provided
medication [31]. Possibly, after a while, pharmacotherapy
does not require the patient to be seen frequently in mental
health care providers and they will probably only return for
maintenance appointments. In contrast, psychotherapy and
other forms of therapy require multiple face-to-face con-
tacts and are often more frequently provided.
The similar HR found for different treatment categories
(5–250 min, 251–500 min, 501–750 min and
751–1000 min) in the total group, patients who received
psychotherapy only and patients who received other ther-
apy is in contrast with other findings in naturalistic treat-
ment settings. Those findings showed that treatment
allocation is associated with severity of symptoms [15];
patients with more severe complaints received the most
prolonged treatment [15]. Based on these results, we might
expect that patients who received a longer treatment
duration would be more likely to return into mental health
care, due to the complexity of symptoms. One possible
explanation is that patients who received a shorter treat-
ment did not receive enough sessions to fully recover [13]
or that their treatment was terminated too early, and that a
longer duration of treatment might protect from return into
mental health care. Another explanation is that the patients
who dropped out of treatment (and consequently received a
shorter duration) were at higher risk for return due to the
complexity of symptoms. However, the results of the
sensitivity analyses (excluding patients who dropped out of
treatment) were comparable on almost all determinants. A
third explanation might be that some patients have a more
frequent pattern of health care use, where they receive a
shorter initial duration of treatment but return more often
for one or two booster sessions. In line with this idea, the
multidisciplinary guidelines for depression emphasize the
importance of relapse prevention [31]. Unfortunately, it is
not possible to test this hypothesis in the present study.
Based on the findings of our study, at least some
patients might benefit more from a longer duration of
treatment. However, an important consideration is that the
effects found for all the analyses were relative small.
Furthermore, population characteristics showed that only
a minority of patients received treatment between
5–250 min (14 %) and between 251–500 min (21 %).
Therefore, and because of the naturalistic design of the
study, it is not possible to draw causal conclusions about
the use of brief therapies en the risk of relapse into
repeated mental health care use. However, our findings do
suggest that brief therapies may not be sufficient for every
patient when we look at the long-term outcome. Further
research, preferably in a controlled setting of a RCT,
should examine if brief therapies are associated with
repeated mental health care use.
This study has several strengths and limitations that need
to be considered. An important strength of the study is that
we examined a naturalistic cohort. Furthermore, it was a
large sample and included specialized mental health provi-
ders in the Netherlands. A disadvantage of this design is that
the registration system was not specifically designed for
scientific research purposes. As a consequence, we had no
control over the registration of the data (e.g., there was no
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possibility to check registration errors or misclassifications)
which may have influenced the results. However, the relia-
bility of the data in the registration is tested by the insurance
companies periodically in order to verify the claims made.
This is no guarantee of the reliability of the data, but does
ensure that much effort goes into the quality of the data that
are stored in the DTC information. We examined the asso-
ciation of brief treatment and return into mental health care,
but had no control over who received brief or prolonged
treatment. Variability may exist in how practitioners will
organize and close the treatment, especially for patients with
severe symptoms [15]. In addition, we followed every
individual patient without additional background informa-
tion (e.g., history of depression and previous help-seeking
behavior). Finally, with the data available to us at the time of
the analysis, the number of practitioners and institutions was
unknown. Therefore, it was not possible to control for the
potentially nested structure of the data.
Conclusion
The findings of this study provide some indication that
patients who receive a longer duration of treatment may be
less likely to return into mental health care. However,
further research, preferably using controlled and random-
ized designs, is needed to determine if the trend towards
lower intensive and brief treatment is associated with more
relapse and return into mental health care.
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